Aureka Biotechnologies has secured $35 million in Series A+ funding, led by Sequoia China, with participation from existing and new investors. The company plans to use these funds to enhance its AI-driven antibody design platform, AuraIDE™, and its underlying foundation models and agent capabilities. Aureka aims to accelerate drug discovery by integrating its wet-lab experimental platforms with AI to create rapid feedback loops, significantly reducing the traditional 5-10 year validation cycle for new drug candidates. AI
影响 Accelerates AI-driven drug discovery timelines and validates the commercial potential of AI in pharmaceutical development.
排序理由 Significant funding round for an AI-driven biotech company.
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →